|
|
|
18/12/2006
LUMINEX AND EXIQON INTRODUCE MICRORNA PRODUCT LINE.
 Read more »
11/12/2006
Symphogen and Meiji Kaisha enter agreement for recombinant polyclonal antibody product.
Read more »
30/11/2006
ARPIDA ANNOUNCES POSITIVE RESULTS IN FIRST PHASE III TRIAL OF ICLAPRIM IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS.
Read more »
28/11/2006
Aerocrine - Amerikanska läkare får betalt för att utföra astmatest.
Read more »
28/11/2006
Aerocrine - new CPT code awarded.
Read more »
23/11/2006
NeuroSearch effects the first milestone payment of SEK 75 million in cash to the former owners of Carlsson Research AB.
Read more »
10/11/2006
Biopheresis receives a 0.5 million Euros grant from German federal government.
Read more »
24/10/2006
Doxa and the pharmaceutical company Orexo build a platform for new, innovative drugs by developing a unique drug delivery technology.
Read more »
19/09/2006
Luminex and Exiqon announce development and commercialization agreement.
Read more »
23/08/2006
NeuroSearch to Acquire Carlsson Research.
Read more »
08/05/2006
Financing Bolsters AdvanDx Position in Pharmacodiagnostics.
Read more »
08/05/2006
BioPheresis Technologies Inc. names Bernhard Ehmer Chief Executive Officer.
Read more »
07/03/2006
Arpida announces full year 2005 financial results.
Read more »
15/02/2006
Arpida presents additonal clinical evidence of good bioavailability of oral Iclaprim.
Read more »
02/02/2006
Biovitrum and Symphogen Enter Co-development and Commercialization Agreement for Recombinant Polyclonal Antibodies for the treatment of certain blood disorders.
Read more »
26/01/2006
Arpida confirms good bioavailability of Iclaprim from an oral formulation.
Read more »
12/01/2006
Arpida updates scientific community on progress with iclaprim.
Read more »
10/01/2006
Symphogen's success in manufacturing consistent batches of polyclonal antibodies for clinical trials attracts new USD 25 million investment.
Read more »
09/01/2006
SLS Venture invests in promising US oncology company.
Read more »
|
